Dr. Iván R. González· @Dr_Ivanoncologo · X·· 12 hours agoScore70
Body
Promising data from #ESMO26 Presidential Symposium I: INTerpath-001 showed a 42% reduction in recurrence or death with individualized mRNA neoantigen therapy + pembrolizumab vs pembrolizumab alone in resected stage IIB–IV melanoma (HR 0.58; p<0.001). OS data remain immature.
61 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: Dr. Iván R. González · x.com